A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects with Selected Advanced Solid Tumors
A study for patients with advanced solid tumors using study drug MEDI0562
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAQ4411
U.S. Govt. ID: NCT02318394
Contact: Naiyer Rizvi: 646-317-3141 / nar2144@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to determine the best dose of MEDI0562 that is safe and tolerable in subjects with advanced solid tumors. This study will also evaluate hows much MEDI0562 is in your blood at various times (which is called pharmacokinetics), whether your immune system becomes activated following administration of MEDI0562, whether your body produces antibodies (proteins produced by your immune system) against MEDI0562, as well as the effect MEDI0562 has on your cancer.
This study is closed
Investigator
Do You Qualify?
Have you been diagnosed with advanced solid tumors? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Naiyer Rizvi
nar2144@cumc.columbia.edu
646-317-3141
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE